Loading stock data…
OPRX
$7.60-0.27 (-3.43%)
Market ClosedLast close Sep 8
OptimizeRx Corporation operates as a digital healthcare technology company.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
OptimizeRx Corporation in the Healthcare sector is trading at $7.60 with a market capitalization of $100M. Wall Street consensus targets $12.40 (5 analysts), implying a +63.2% move over the next 12 months. The stock is currently near its 52-week low of $4.54, remaining 8.5% below its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +63.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 33) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $19.84M↓ | $32.24M↑ | $26.07M↓ | $29.20M↑ | $21.93M |
| Gross Profit | $14.93M↓ | $24.10M↑ | $17.52M↓ | $18.64M↑ | $13.34M |
| Operating Income | $396,000↓ | $8.94M↑ | $2.05M↓ | $3.19M↑ | -$2.10M |
| Net Income | -$495,000↓ | $5.02M↑ | $779,000↓ | $1.53M↑ | -$2.20M |
Peer Comparison
JNJUNHPFE
Fundamentals
OptimizeRx Corporation operates as a digital healthcare technology company. It offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, wh...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$99.83M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
5.27%
Volume
Today's trading volume
99,326
Recent News
OptimizeRx (OPRX) Q2 2026 Earnings Call Transcript
AI software revenue grew 25% despite overall quarterly decline from customer inactivity.
OptimizeRx Corporation Q2 2026 Earnings Call Summary
Moby summary of OptimizeRx Corporation's Q2 2026 earnings call
OptimizeRx Corp (OPRX) (Q2 2026) Earnings Call Highlights: Navigating Revenue Headwinds with ...
Despite a 30% revenue decline, OptimizeRx Corp (OPRX) reaffirms full-year guidance, driven by AI-powered product growth and a strengthened balance sheet.
OptimizeRx Q2 Earnings Call Highlights
OptimizeRx (NASDAQ:OPRX) reported second-quarter fiscal 2026 revenue of $20.5 million, down 30% from $29.2 million a year earlier, while adjusted EBITDA totaled $4.9 million, management said on its earnings call. The company reaffirmed its full-year revenue outlook of $95 million to $100 million and
OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates
OptimizeRx (OPRX) delivered earnings and revenue surprises of +45.46% and +0.11%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?